RTC
EBS icon

Riverview Trust Company’s Emergent Biosolutions EBS Stock Holding History

Riverview Trust Company’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-334
Closed -$14K – 750
2022
Q1 		$14K Hold
334
– – 0.01% 643
2021
Q4 		$15 Hold
334
– – 0.01% 216
2021
Q3 		$17K Hold
334
– – 0.02% 208
2021
Q2 		$21K Hold
334
– – 0.02% 200
2021
Q1 		$31K Hold
334
– – 0.03% 180
2020
Q4 		$30K Buy
+334
New +$30.7K 0.03% 176

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Riverview Trust Company's EBS Position: Q2 2022 in Review

Riverview Trust Company sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 334 shares — an estimated $14K sold.

Riverview Trust Company first reported a position in EBS in Q4 2020 and held it in 6 quarters. The position peaked at $31K in Q1 2021. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Riverview Trust Company reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Riverview Trust Company sold 334 Emergent Biosolutions shares in Q2 2022, an estimated $14K.
  • Riverview Trust Company first reported a position in Emergent Biosolutions in Q4 2020 and held it in 6 quarters.
  • Riverview Trust Company's Emergent Biosolutions position peaked at $31K in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Riverview Trust Company's 13F filing for Q2 2022, filed 27 Jul 2022.